Key Driver Reshaping the Neulasta Market in 2025: Rising Cancer Incidence To Drive Market Growth

How Is the Neulasta Market Projected to Grow, and What Is Its Market Size?
In recent times, there's been an $XX expansion in the Neulasta market size. Starting with a worth of $XX million in 2024, it's projected to reach $XX million in 2025, progressing at a compound annual growth rate (CAGR) of $XX%. The evolution during this historic period is associated with the increasing instances of chemotherapy-induced neutropenia, rising cases of cancer worldwide, increased comprehension of neutropenia threats linked to cancer treatment, availability of state-sponsored funding for biologicals, and swift acceptance of biologics in developed regions.

The Neulasta market is projected to experience an $XX% compound annual growth rate (CAGR), expanding to $XX million by 2029. The predicted expansion during the forecast period can be linked to a surge in biosimilars in budding markets, the escalating necessity for cost-effective cancer-supportive care, an upward curve in global healthcare expenditure, a rise in the number of biosimilar approvals by regulatory bodies, and an increase in patient awareness about biosimilar alternatives. The forecast period also foresees significant trends such as the introduction of prefilled syringes for simplified administration, innovation in drug delivery systems, like on-body injectors, the digital platform engagement for patient education, application of artificial intelligence in biologics research and development and supply chain enhancement, and strategic alliances among biologic and biosimilar businesses.

What Are the Key Drivers Behind the Growth of the Neulasta Market?
The growing occurrence of cancer is propelling the expansion of the neulasta market. Cancer is a collective term for various diseases marked by the abnormal growth of cells that have the potential to spread throughout the body. Factors like aging, unhealthy living habits, and environmental aspects are driving the surge in cancer prevalence. Biosimilars like pegfilgrastim, or neulasta, play a vital role for cancer patients undergoing chemotherapy as it helps forestall chemotherapy-induced neutropenia by promoting the generation of white blood cells and lowering infection susceptibility. For example, the Australian Institute of Health and Welfare, a national agency providing information and statistics on health and welfare in Australia, reported in August 2024 that by 2034, Australia is estimated to experience approximately 209,000 new cancer cases. This is a significant increase from the predicted 169,000 cases in 2024. Furthermore, it is projected that in 2024, nearly 3 in every ten deaths in Australia will be due to cancer. Thus, the escalating prevalence of cancer is set to stimulate the growth of the neulasta market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20159&type=smp

Who Are the Major Industry Players Fueling Neulasta Market Expansion?
Major companies operating in the neulasta market include Amgen Inc.

How Is the Neulasta Market Evolving?
Progressing drug delivery technologies like prefilled autoinjectors have become prevalent in the neulasta market as a mean to stay competitive. These are self-injection devices that come loaded with medication for ease of self-administration by patients. For instance, Coherus Biosciences, a biopharmaceutical operation out of the United States, reported in March 2023 that the FDA had greenlighted a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv). This approval is for the treatment and prevention of febrile neutropenia, a frequent side-effect of chemotherapy. This autoinjector facilitates patients receiving pegfilgrastim a day subsequent to their chemotherapy, thereby reducing febrile neutropenia risks. The device is equipped for immediate delivery of a full pegfilgrastim dose with a reliable push-on-skin activation.

How Is the Segmentation of the Neulasta Market Defined?
The neulasta market covered in this report is segmented -

1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications
2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Pediatric Patients

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neulasta-global-market-report

What Is the Leading Region in the Neulasta Market?
North America was the largest region in the neulasta market in 2024. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Neulasta Global Market Report?

- Market Size Analysis: Analyze the neulasta Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the neulasta market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall neulasta market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the neulasta market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20159

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.